| |
Description
The MINDSET-01 clinical trial is a fifteen month, double-blind, placebo-controlled trial. The trial will be followed by a 12 month active treatment open label extension period. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression. |
|
